Difference between revisions of "Raltitrexed (Tomudex)"
Warner-admin (talk | contribs) m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==") |
m |
||
Line 15: | Line 15: | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
+ | ==History of changes in EMA indication== | ||
+ | *1995-11-08: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' TDX, ZD 1694 | *'''Code names:''' TDX, ZD 1694 | ||
Line 31: | Line 33: | ||
[[Category:Malignant pleural mesothelioma medications]] | [[Category:Malignant pleural mesothelioma medications]] | ||
− | [[Category:EMA approved | + | [[Category:EMA approved in 1995]] |
[[Category:Health Canada approved drugs]] | [[Category:Health Canada approved drugs]] |
Revision as of 12:20, 11 June 2023
General information
Class/mechanism: Antimetabolite, inhibitor of thymidylate synthase. Raltitrexed is a quinazoline folate analogue which inhibits thymidylate synthase (TS). TSis an enzyme involved in the synthesis of thymidine triphosphate (TTP), a nucleotide required exclusively for DNA synthesis. Inhibiting TS causes DNA damage and cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
No information available.
Diseases for which it is established (work in progress)
Diseases for which it is used
History of changes in EMA indication
- 1995-11-08: EURD
Also known as
- Code names: TDX, ZD 1694
- Generic name: raltitrexed disodium
- Brand name: Tomudex